Hepatitis C Treatment: Current and future perspectives

Virology Journal

Volumn 7, Issue , 2010, Pages

  Munir, Saira ^a   Saleem, Sana ^a   Idrees, Muhammad ^a   Tariq, Aaliyah ^a   Butt, Sadia ^a   Rauff, Bisma ^a   Hussain, Abrar ^a   Badar, Sadaf ^a   Naudhani, Mahrukh ^a   Fatima, Zareen ^a   Ali, Muhmmad ^a   Ali, Liaqat ^a   Akram, Madiha ^a   Aftab, Mahwish ^a   Khubaib, Bushra ^a   Awan, Zunaira ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBINTERFERON ALPHA2B; ALPHA INTERFERON; ANTIFIBROTIC AGENT; ANTIVIRUS AGENT; CASPASE INHIBITOR; CONVENTIONAL INTERFERON; HEPATITIS VACCINE; IMMUNOMODULATING AGENT; INTERFERON; LACCASE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROANTHOCYANIDIN; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; TARIBAVIRIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; ALPHA2A INTERFERON; ALPHA2B INTERFERON; MACROGOL DERIVATIVE;

ABDOMINAL PAIN; ACUTE PSYCHOSIS; ALTERNATIVE MEDICINE; ANEMIA; ANOREXIA; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ANXIETY DISORDER; ARTHRALGIA; BLOOD TRANSFUSION; CLINICAL TRIAL; COMPETITIVE INHIBITION; CYTOPENIA; DEPRESSION; DEVELOPING COUNTRY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRY SKIN; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FETUS DISEASE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HERBAL MEDICINE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INJECTION SITE REACTION; INSOMNIA; INTERNAL RIBOSOME ENTRY SITE; INTRAVENOUS DRUG ABUSE; IRRITABILITY; KIDNEY DYSFUNCTION; LARYNGITIS; LEUKOPENIA; LIVER BIOPSY; LONG TERM CARE; MEDICINAL PLANT; MONOTHERAPY; MYALGIA; NAUSEA AND VOMITING; NEEDLESTICK INJURY; NEUTROPENIA; PATHOGENESIS; PLEUROTUS OSTREATUS; PRURITUS; PSYCHOSIS; REVIEW; RHODIOLA KIRILOWII; SIDE EFFECT; SKIN REDNESS; SUICIDE; SUICIDE ATTEMPT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS CARCINOGENESIS; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; DRUG COMBINATION; METHODOLOGY; TREATMENT OUTCOME;

FLAVIVIRIDAE; HEPATITIS C VIRUS; RHODIOLA KIRILOWII;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 77958614232     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-296     Document Type: Review

References (58)

1. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. T Asselah E Estrabaud I Bieche M Lapalus S De Muynck M Vidaud D Saadoun V Soumelis P Marcellin, Liver Int 2010 ISSN 1478-3223 20633102
2. Epidemiology of hepatitis C virus infection. MJ Alter, World J Gastroenterol 2007 13 17 2436 41 17552026
3. Hepatitis C virus infection: the new global epidemic. AA Butt, Expert Rev Anti Infect Ther 2005 3 241 9 10.1586/14787210.3.2.241 15918781
4. New Therapies for Hepatitis C Virus Infection. V Soriano Marion G Peters S Zeuzem, Clinical Infectious Diseases 2009 48 313 20 10.1086/595848 19123867
5. Viral hepatitis in HIV infection. M Koziel M Peters, N Engl J Med 2007 356 1445 54 10.1056/NEJMra065142 17409326
6. Hepatitis B and C virus in West-Central Turkey: Seroprevalence in healthy individuals admitted to a university hospital for routine health checks. N Demirtürk T Demirdal D Toprak M Altindi OC Aktepe, Turk J Gastroenterol 2006 17 267 72 17205404
7. Hepatitis C virus in Zimbabwe. IT Gangaidzo VM Moyo H Khumalo T Saungweme Z Gomo T Rouault VR Gordeuk, Cent Afr J Med 1997 43 122 5 9505450
8. General seroprevalence ofhepatitis C and hepatitis B virus infections in population. N Khokhar ML Gill GJ Malik, J Coll Physicians Surg Pak 2004 14 534 6 15353136
9. Clinical course of hepatitis C virus during the first decade of infection: cohort study. HE Harris ME Ramsay N Andrews KP Eldridge, BMJ 2002 324 1 6 10.1136/bmj.324.7335.450 11777781
10. Treatment and vaccination for hepatitis C: present and future. A Jawaid AK Khuwaja, J Ayub Med Coll Abbottabad 2008 20 1 129 33 19024206
11. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. MP Manns JG McHutchison SC Gordon VK Rustgi M Shiffman R Reindollar ZD Goodman K Koury M Ling JK Albrecht, Lancet 2001 358 9286 958 965 10.1016/S0140-6736(01) 06102-5 11583749 (Pubitemid 32913521)
12. A novel small molecule inhibitor of hepatitis C virus entry. CJ Baldick MJ Wichroski A Pendri AW Walsh J Fang CE Mazzucco KA Pokornowski RE Rose BJ Eggers M Hsu W Zhai G Zhai SW Gerritz MA Poss NA Meanwell MI Cockett DJ Tenney, PLoS Pathog 2010 6 9 pii:e1001086.10.1371/journal.ppat.1001086 10.1371/journal.ppat.1001086 20838466
13. Management of hepatitis C 2002 (June 10-12, 2002). National Institutes of Health Consensus Development Conference Statement, Gastroenterology 2002 123 6 2082 2099 10.1053/gast.2002.1232082 12454863
14. An in vitro model of hepatitis C virion production. T Heller S Saito J Auerbach T Williams TR Moreen A Jazwinski B Cruz N Jeurkar R Sapp G Luo TJ Liang, Proc Natl Acad Sci USA 2005 102 2579 83 10.1073/pnas.0409666102 15701697
15. In vitro replication models for the hepatitis C virus. P Sheehy B Mullan I Moreau E Kenny-Walsh F Shanahan M Scallan LJ Fanning, J Viral Hepa 2007 14 1 2 10 10.1111/j.1365-2893.2006.00807.x (Pubitemid 46012355)
16. High antibody level: an accurate serologic marker of viremia in asymptomatic people with hepatitis C infection. AM Contreras RJ Ochoa-Jiménez A Celis C Méndez L Olivares CE Rebolledo I Hernandez-Lugo AI Aguirre-Zavala R Jiménez-Méndez RT Chung, Transfusion 2010 50 6 1335 43 10.1111/j.1537-2995.2009.02571.x 20088833
17. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. MW Fried ML Shiffman KR Reddy C Smith G Marinos FL Gonçales Jr D Häussinger M Diago G Carosi D Dhumeaux A Craxi A Lin J Hoffman J Yu, N Engl J Med 2002 347 13 975 982 10.1056/NEJMoa020047 12324553
18. Natural history of hepatitis C. LB Seeff, Am J Med 1999 107 6B 10S 15S 10.1016/S0002-9343(99)00374-5 10653449
19. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. M Idrees S Riazuddin, BMC Infectious Diseases 2008 8 69 10.1186/1471-2334-8-69 18498666
20. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. NN Zein J Rakela EL Krawitt KR Reddy T Tominaga DH Persing, Ann Intern Med 1996 125 634 639 8849147
21. A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. M Idrees S Riazuddin, BMC Gastroenterology 2009 9 5 10.1186/1471-230X-9-5 19152711
22. Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection. RJ Brown VS Juttla AW Tarr R Finnis WL Irving S Hemsley DR Flower P Borrow JK Ball, J Gen Virol 2005 86 7 1931 42 10.1099/vir.0.80957-0 15958671
23. Mechanisms of Liver Injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. J Choi JHO James, J Physiol Gastrointest Liver Physiol 2006 290 847 G851 10.1152/ajpgi.00522.2005
24. The immunopathogenesis of hepatitis C virus infection. DR Nelson, Clin Liver Dis 2001 5 931 53 10.1016/S1089-3261(05)70202-6 11685802
25. Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. S De Lucas J Bartolome V Carreno, J Infect Dis 2005 191 93 9 10.1086/426509 15593009
26. The hepatitis C virus NS3/4A protease complex interferes with pathways of the innate immune response. P Karayiannis, J Hepatol 2005 43 743 5 10.1016/j.jhep.2005.07.004 16102870
27. Epidemiology of hepatitis C virus infection in Pakistan. NS Raja KA Janjua, J Microbiol Immunol Infect 2008 41 4 8 18327420
28. General seroprevalance of Hepatitis C & hepatitis B virus infections in Pakistan. N Khokhar ML Gill KJ Malik, J Coll Phy Surg Pak 2004 14 9 534 15
29. Hepatitis C in hospital employees with needle stick injuries. K Kiyosawa T Sodeyama E Tanaku, Ann intern Med 1991 115 367 9 1907441
30. Hepatitis C. RU Din A Kamal HU Khan, Gomal Journal of Medical Sciences 2004 2 1 27 29
31. Lack of transmission of hepatitis C in household contacts of children with homozygous beta-thalassaemia. DA Papanastasiou I Spiliopoulou S Katinakis A Karana-Ginopoulou M Repanti, Acta Haematol 1997 97 3 168 73 10.1159/000203675 9066712
32. Transmission of hepatitis C virus from mothers to infants. H Ohto S Terazawa N Sasaki N Sasaki K Hino C Ishiwata M Kako N Ujiie C Endo A Matsui, N Engl J Med 1994 330 744 750 10.1056/NEJM199403173301103 8107740 (Pubitemid 24080220)
33. Hepatitis C virus RNA in saliva and breast milk of Hepatitis C carriers. S Ogasawara Kagem Kasai ki, Lancet 1993 341 561 10.1016/0140-6736(93)90324-A 8094800
34. Frequency of hepatitis "C" in Buner, NWFP. N Muhammad MA Jan, J Coll Physicians Surg Pak 2005 15 11 4 15670516
35. Dentistry as a possibl route of hepatitis C transmission in Pakistan. AK Butt AA Khan SY Khan I Sharea, Int Dent J 2003 53 141 4 12873110
36. Spectrum of hepatocellular carcinoma at Shifa International Hospital, Islamabad. N Khokhar I Aijazi ML Gill, J Ayub Med Coll Abbottabad 2003 15 1 4 15067821
37. VGDN Consortium: Social networks shape the transmission dynamics of hepatitis C virus. CM Romano IM de Carvalho-Mello LF Jamal FL de Melo A Iamarino M Motoki JR Pinho EC Holmes PM de Andrade Zanotto, PLoS One 2010 5 6 e11170.10.137/journal.pone 10.1371/journal.pone.0011170
38. Diagnostic strategies in Hepatitis C virus infection. LS Iancu, Rev Med Chir Soc Med Nat Iasi 2001 105 1 37 42 12092156
39. Diagnostic tests for Hepatitis C. DR Gretch, Hepatology 1997 299 1 435 475
40. Diagnosis of occult hepatitis C without the need for a liver biops. I Castillo J Bartolomé JA Quiroga G Barril V Carrẽo, J Med Virol 2010 82 9 1554 9 10.1002/jmv.21866 20648609
41. Therapy of hepatitis - meta analysis of interferon alpha 2b trials. RL Caritter SS Emerson, Hepatology 1997 26 31 835 85
42. Randomized trial of interferon alpha-2b plus ribavirin for 48 weeks versus interferon alpha-2b plus placebo for 48 weeks for the treatment of chronic hepatitis-C virus. T Poynard, Lancet 1998 351 1426 10.1016/S0140- 6736(98)07124-4 (Pubitemid 28510876)
43. Viral Hepatitis. Current diagnosis and treatment. RK Fox TL Wright, Gastroenterology 2003 2 446 562
44. Management of chronicnhepatitis C: Consensus guidelines. M Sherman S Shafran K Burak K Doucette W Wong N Girgrah E Yoshida E Renner P Wong M Deschnes, Can J Gastroenterol 2007 21 Suppl C 25C 34C 17568824
45. A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. M Idrees S Riazuddin, BMC Gastroenterol 2009 9 5 10.1186/1471-230X-9-5 19152711
46. PSG consensus statement on management of hepatitis C virus infection - 2003. S Hamid M Umar A Alam A Siddiqui H Qureshi J Butt, J Pak Med Assoc 2004 54 146 150 15129876
47. Sustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani population. Bader Faiyaz Zuberi Faisal Faiyaz Zuberi Sajjad Ali Memon Muhammad Hafeez Qureshi Sheikh Zafar Ali Afsar Salahuddin, World J Gastroenterol 2008 14 14 2218 2221 10.3748/wjg.14.2218 18407597
48. Peg interferon alpha-2a (40 KD) in combination with ribavirin -Efficacy and safety results from phase 3, randomized double blind, multicenter study examining effect of duration and ribavirin dose. SJ Hadziyannis H Cheinquer T Morgan, J Hepatol 2002 36 1 3 10.1016/S0168-8278(02)80001-0
49. Sustained virologic response rates with albinterferon alfa-2b plus ribavirin treatment in IFN-nave chronic hepatitis C genotype 1 patients. S Zeuzem E Yoshida Y Benhamou, Hepatology 2007 46 l 317A
50. Murphy B:Virological response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. R Gish S Arora K Rajender RN David OB Christopher Y Xu, J Hepatol 2007 47 51 9 10.1016/j.jhep.2007.02.018 17470380
51. Hepatitis-C virus serotype 2 response more favourably to interferone; a therapy. E Orito N Mizoguchi, J Hepatol 1994 21 130 2 10.1016/S0168-8278(94) 80149-5 7525694
52. Oyster mushroom laccase inhibits hepatitis C virus entry into peripheral blood cells and hepatoma cells. EM El-Fakharany BM Haroun TB Ng ER Redwan, Protein Pept Lett 2010 17 8 1031 9 10.2174/092986610791498948 20156183
53. Proanthocyanidin from Blueberry Leaves Suppresses Expression of Subgenomic Hepatitis C Virus RNA. M Takeshita YO Ishida E Akamatsu Y Ohmori M Sudoh H Uto H Tsubouchi H Kataoka, journal of biological chemistry 2009 284 32 21165 21176 10.1074/jbc.M109.004945 19531480
54. Activity of compounds from Chinese herbal medicine Rhodiola kirilowii (Regel) Maxim against HCV NS3 serine protease. G Zuo Z Li L Chen X Xu, Antiviral Res 2007 76 1 86 92 10.1016/j.antiviral.2007.06.001 17624450
55. Coinfection with hepatitis B and C, C and D viruses result in severe chronic liver disease and responds poorly to interferon. M Welfman A Brotodihardjo E Crewe, J Vviral Hept 1995 2 39 45 10.1111/j.1365-2893.1995. tb00070.x
56. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. AU Neumann NP Lam H Dahari DR Gretch TE Wiley TJ Layden AS Perelson, Science 1998 282 103 7 10.1126/science.282.5386.103 9756471
57. specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. CM Lange Sarrazin C. S Zeuzem, Aliment Pharmacol Ther 2010 32 14 28 20374226
58. Interference of hepatitis C vius RNA replication by short interfering RNAs. SB Kapadia A Brideau-Andersen FV Chisari, Proc Natl Acad Sci USA 2003 100 4 2014 8 10.1073/pnas.252783999 12566571